# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen downgrades Interpace Biosciences (OTC:IDXG) from Buy to Neutral.
Interpace Diagnostics Gr (NASDAQ:IDXG) reported $9.80 million in sales this quarter. This is a 6.52 percent increase over sales...
Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:I...
HC Wainwright & Co. analyst Yi Chen maintains Interpace Biosciences (OTC:IDXG) with a Buy and raises the price target fr...
Interpace Biosciences, Inc., a leader in molecular testing for cancer risk, today announced that it has expanded its relationsh...
Gainers
Gainers TDH Holdings, Inc. (NASDAQ: PETZ) shares climbed 302% to $12.58 after jumping more than 25% on Tuesday.